Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors
This study evaluates the association of Biopharma company valuation with the lead drug’s development stage, orphan status, number of indications, and disease area. We also estimated annual returns Bioentrepreneurs and investors can expect from founding and investing in drug development ventures.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
11. January 2022
|
| In: |
Therapeutic innovation & regulatory science
Year: 2022, Volume: 56, Issue: 2, Pages: 313-322 |
| ISSN: | 2168-4804 |
| DOI: | 10.1007/s43441-021-00364-y |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s43441-021-00364-y Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s43441-021-00364-y 
|
| Author Notes: | Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli |
| Summary: | This study evaluates the association of Biopharma company valuation with the lead drug’s development stage, orphan status, number of indications, and disease area. We also estimated annual returns Bioentrepreneurs and investors can expect from founding and investing in drug development ventures. |
|---|---|
| Item Description: | Gesehen am 29.04.2024 |
| Physical Description: | Online Resource |
| ISSN: | 2168-4804 |
| DOI: | 10.1007/s43441-021-00364-y |